Shenzhen Shenxin Biotechnology Co. Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shenzhen Shenxin Biotechnology Co. Ltd.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice